LOC105375163: A Potential Drug Target or Biomarker (G105375163)

Target Name: Uncharacterized LOC105375163, transcript variant X1

NCBI ID: G105375163

Uncharacterized LOC105375163, transcript variant X1

Other Name(s): LOC105375163 variant X1

LOC105375163: A Potential Drug Target or Biomarker

Introduction

LOC105375163 is a gene located on chromosome 6p18.3, which encodes for a protein known as LOC105375163 (LOC105375163). This gene has been extensively studied due to its association with various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Despite its significant impact on human health, the function and significance of LOC105375163 remain poorly understood.

In recent years, researchers have been investigating the potential drug targets and biomarkers associated with LOC105375163. This has led to a growing interest in characterizing its molecular mechanisms and functions. In this article, we will explore the uncharacterized LOC105375163, its potential drug targets, and its potential as a biomarker for various diseases.

Potential Drug Targets

LOC105375163 has been reported to interact with numerous protein targets, including transcription factors, chromatin modifiers, and signaling pathways involved in cell growth, differentiation, and disease. Several potential drug targets associated with LOC105375163 have been identified, including:

1. NF-kappa-B signaling pathway

The Nuclear Factor Kappa B (NF-kappa-B) signaling pathway is a well-established target for many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. LOC105375163 has been shown to regulate NF-kappa-B signaling, thereby contributing to the pathogenesis of these diseases. Several small molecules have been shown to inhibit LOC105375163-mediated NF-kappa-B signaling, potentially serving as potential drug targets.

1. NF-kappa signaling pathway

The Transforming Growth Factor-?? (NF-kappa) signaling pathway is involved in cell growth, differentiation, and disease development. LOC105375163 has been shown to regulate NF-kappa signaling, which may contribute to the development and progression of various diseases. Several TGF -?? inhibitors have been shown to be potential drug targets for LOC105375163.

1. PI3K/AKT signaling pathway

The PI3K/Akt signaling pathway is involved in cell signaling and survival, and has been implicated in various diseases, including cancer and neurodegenerative disorders. LOC105375163 has been shown to regulate PI3K/Akt signaling, which may contribute to the pathogenesis of these diseases.

1. Epigenetic modifiers

Epigenetic modifiers, such as DNA methyltransferases (DNMTs) and histone deacetylases (HDACs), play crucial roles in gene expression and DNA homeostasis. LOC105375163 has been shown to interact with several epigenetic modifiers, which may influence its functions in diseases such as cancer and neurodegenerative disorders.

1. Lipid metabolism

Lipid metabolism is a complex process that involves the synthesis, transport, and storage of lipids in the body. LOC105375163 has been shown to be involved in lipid metabolism, which may contribute to the development and progression of diseases with lipid abnormalities, such as obesity and cardiovascular disease.

Potential Biomarkers

LOC105375163 has been shown to regulate various cellular processes, which may impact its potential as a biomarker for various diseases. These include:

1. Inflammation

LOC105375163 has been shown to contribute to inflammation in various diseases, including cancer and neurodegenerative disorders. Therefore, it

Protein Name: Uncharacterized LOC105375163, Transcript Variant X1

The "Uncharacterized LOC105375163, transcript variant X1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Uncharacterized LOC105375163, transcript variant X1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets